Related Experiment Video
Updated: May 24, 2026

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
Published on: August 23, 2024
Protocadherin 7 Positive Membranous Nephropathy in China
Yongzhong Zhong1,2, Yunyun Liu3, Dan Zhou1
1National Clinical Research Center for Kidney Diseases, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China.
Background And Hypothesis:
Protocadherin-7 (PCDH7) is a newly discovered rare autoantigen in membranous nephropathy (MN). Data about PCDH7-positive MN are limited. We investigate the clinicopathological characteristics and outcomes of PCDH7-positive MN.
Methods:
Biopsy-confirmed PCDH7-positive MN cases identified between January 2023 and October 2024 were retrospectively analysed. Data on demographic characteristics and clinicopathological variables were collected. Subgroup analysis was performed between isolated PCDH7-positive MN and PLA2R/PCDH7 dual-positive MN cases. Serum anti-PCDH7 antibody levels were measured.
Results:
Among 690 PCDH7-tested patients, 19 (2.75%) showed PCDH7 positivity: 7 with isolated PCDH7-positive MN and 12 with PLA2R/PCDH7 dual-positive MN. The cohort (median age 52 years; 63% male) exhibited a median serum albumin level 34.3 g/L, creatinine 0.78 mg/dL, and proteinuria 2.25 g/24h, with 1 patient having eGFR < 60 mL/min/1.73m² and 4 presenting nephrotic syndrome. Potential secondary factors were identified in 6 patients (3 with autoimmune disease, 1 with malignancy, 2 with infections); dominant IgG deposition was IgG1 in isolated PCDH7-positive MN versus IgG4 in PLA2R/PCDH7 dual-positive cases. Anti-PCDH7 antibodies were seropositive in 7 patients (5 in isolated PCDH7-positive MN and 2 in PLA2R/PCDH7 dual-positive MN). During a median 13-month follow-up period, 84% (16/19) achieved partial or complete remission.
Conclusions:
PCDH7-positive MN shows clinicopathological heterogeneity. PCDH7 can be detected in both PLA2R-positive and PLA2R-negative MN patients, with similar positive rates between the two groups. No consistent clinical presentation was observed in PCDH7-positive patients; instead, this group included a variety of potential secondary conditions. Additionally, anti-PCDH7 antibody levels did not correlate with clinical manifestations and outcomes in our preliminary observation.
Insights
Protocadherin-7 (PCDH7) is a rare autoantigen in membranous nephropathy (MN). This study found PCDH7-positive MN cases exhibit diverse clinical features and outcomes, with 84% achieving remission.
Area of Science:
- Nephrology
- Immunology
- Pathology
Background:
- Protocadherin-7 (PCDH7) is a newly identified autoantigen in membranous nephropathy (MN).
- Limited data exists on the characteristics and outcomes of PCDH7-positive MN.
- This study aims to elucidate the clinicopathological profile of PCDH7-positive MN.
Purpose of the Study:
- To investigate the clinicopathological characteristics of patients with biopsy-confirmed PCDH7-positive membranous nephropathy.
- To analyze the outcomes and identify potential secondary factors in PCDH7-positive MN.
- To compare isolated PCDH7-positive MN with PLA2R/PCDH7 dual-positive MN.
Main Methods:
- Retrospective analysis of biopsy-confirmed PCDH7-positive MN cases from January 2023 to October 2024.
- Collection of demographic, clinical, and pathological data.
- Subgroup analysis of isolated vs. dual-positive MN and measurement of serum anti-PCDH7 antibody levels.
Main Results:
- 19 patients (2.75%) were PCDH7-positive: 7 isolated, 12 dual-positive for PLA2R/PCDH7.
- The cohort presented with variable renal function and proteinuria; 4 patients had nephrotic syndrome.
- 84% of patients achieved partial or complete remission within a median 13-month follow-up.
Conclusions:
- PCDH7-positive MN is clinically heterogeneous and can occur in both PLA2R-positive and PLA2R-negative patients.
- No consistent clinical presentation was observed; secondary conditions were noted in some patients.
- Preliminary findings suggest anti-PCDH7 antibody levels may not correlate with clinical manifestations or outcomes.
More Related Videos
Related Concept Videos
Structure of Cadherins
Cadherins in Tissue Organization
Cell Sorting During Development
Cell sorting plays an...
Nephrotic Syndrome I : Introduction
Diabetic Nephropathy

